106548-41-8

Upstream product

• 14898-67-0 ruthenium trichloride hydrate 
• 1662-01-7 bathophenanthroline 
• 14898-67-0 ruthenium(III) chloride trihydrate 
• 59091-96-2 dichlorotetrakis(dimethylsulfoxide)ruthenium 

Downstream Products

• 919402-72-5 bis(4,7-diphenyl-1,10-phenanthroline)(2,3-bis(2-pyridyl)pyrazine)ruthenium(II)⁽²⁺⁾ 

Relevant academic research and scientific papers

Sensitized electroluminescence on mesoporous oxide Semiconductor films

Forward biasing of a mesoporous TiO2 (anatase) film whose surface is derivatized with a monolayer of the phosphonated ruthenium bipyridyl complex RuL2La?2 with L = 4,7-diphenyl-1,10-phenanthroline and La?2 = 2,2a?2-bipyridine-4,4a?2-

Photodamaging of Mitochondrial DNA to Overcome Cisplatin Resistance by a RuII–PtII Bimetallic Complex

Emerging studies have shown that mitochondrial DNA (mtDNA) is an attractive target for anticancer therapeutics. Herein, a heterobimetallic complex [Ru(dip)2(μ-bpm)PtCl2]Cl2 (RuPt; dip=4,7-diphenyl-1,10-phenanthroline; bpm=2,2′-bipyrimidine) and the corresponding mononuclear complex [Ru(dip)2(bpm)]Cl2 (Ru) have been designed and synthesized. RuPt can bind to mtDNA and damage it both in the dark and upon visible light irradiation. By using a variety of methods, it was demonstrated that RuPt can interfere with the function of mtDNA by decreasing the amplification and copy number of mtDNA, and affecting the transcriptional level of mitochondria-encoded genes. Furthermore, RuPt can disturb the physiological processes of mitochondria and induce caspase-dependent apoptosis in the presence of light. In addition, RuPt shows low systemic toxicity and potent in vivo anticancer potency upon light irradiation. This study provides strong evidence that mtDNA is an important molecular target of RuPt, and photodamaging mtDNA is an effective strategy to overcome cisplatin resistance.

Increased photocatalytic activity in Ru(II),Rh(III) supramolecular bimetallic complexes with terminal ligand substitution

Three new Ru(II),Rh(III) supramolecular bimetallic complexes of the design [(Ph2phen)2Ru(dpp)RhCl2(R2-bpy)](PF6)3(R?=?CH3(Ru-Rh(Me2bpy)), H (Ru-Rh(bpy)), or COOCH3(Ru-Rh(dmeb)); Ph2phen?=?4,7-diphenyl-1,10-phenanthroline; dpp?=?2,3-bis(2-pyridyl)pyrazine; dmeb?=?4,4′-dimethyl ester-2,2′-bipyridine; bpy?=?2,2′-bipyridine; Me2bpy?=?4,4′-dimethyl-2,2′-bipyridine) have been synthesized and analyzed to determine the impact that the polypyridyl terminal ligand (TL) coordinated to the cis-dihalide rhodium(III) metal center has on the photocatalytic activity for water reduction. The bimetallic complexes demonstrate that a correlation exists between the σ-donating ability of the substituted bipyridine ligand, the rate of chloride dissociation upon electrochemical reduction and the activity towards photocatalytic hydrogen production. The weaker σ-donating –COOCH3substituent in Ru-Rh(dmeb) increases the rate constant for Cl?dissociation (k?Cl?=?0.7?s?1) and the amount of H2produced photocatalytically (37?±?4?μmol H2, 63?±?7 turnovers after 20?h; turnovers?=?mol H2/mol photocatalyst) when compared to –H and –CH3substituted complexes Ru-Rh(bpy) (k?Cl?=?0.2?s?1, 21?±?2?μmol H2, 35?±?3 turnovers) and Ru-Rh(Me2bpy) (k?Cl?=?0.2?s?1, 18?±?2?μmol H2, 30?±?4 turnovers), respectively. Varied catalytic activity with respect to the σ-donor capacity of the Rh-TL is attributed to the relative ease of ligand dissociation and the ability to afford rapid electron collection at the Rh metal center.

Increasing the cytotoxicity of Ru(II) polypyridyl complexes by tuning the electronic structure of dioxo ligands

Due to the great potential expressed by an anticancer drug candidate previously reported by our group, namely, Ru-sq ([Ru(DIP)2(sq)](PF6) (DIP, 4,7-diphenyl-1,10-phenanthroline; sq, semiquinonate ligand), we describe in this work a structure-activity relationship (SAR) study that involves a broader range of derivatives resulting from the coordination of different catecholate-type dioxo ligands to the same Ru(DIP)2 core. In more detail, we chose catechols carrying either an electron-donating group (EDG) or an electron-withdrawing group (EWG) and investigated the physicochemical and biological properties of their complexes. Several pieces of experimental evidences demonstrated that the coordination of catechols bearing EDGs led to deep-red positively charged complexes 1-4 in which the preferred oxidation state of the dioxo ligand is the uninegatively charged semiquinonate. Complexes 5 and 6, on the other hand, are blue/violet neutral complexes, which carry an EWG-substituted dinegatively charged catecholate ligand. The biological investigation of complexes 1-6 led to the conclusion that the difference in their physicochemical properties has a strong impact on their biological activity. Thus, complexes 1-4 expressed much higher cytotoxicities than complexes 5 and 6. Complex 1 constitutes the most promising compound in the series and was selected for a more in depth biological investigation. Apart from its remarkably high cytotoxicity (IC50 = 0.07-0.7 μM in different cancerous cell lines), complex 1 was taken up by HeLa cells very efficiently by a passive transportation mechanism. Moreover, its moderate accumulation in several cellular compartments (i.e., nucleus, lysosomes, mitochondria, and cytoplasm) is extremely advantageous in the search for a potential drug with multiple modes of action. Further DNA metalation and metabolic studies pointed to the direct interaction of complex 1 with DNA and to the severe impairment of the mitochondrial function. Multiple targets, together with its outstanding cytotoxicity, make complex 1 a valuable candidate in the field of chemotherapy research. It is noteworthy that a preliminary biodistribution study on healthy mice demonstrated the suitability of complex 1 for further in vivo studies.

Mixed-Ligand Complexes of Ruthenium(II): Factors Governing Binding to DNA

Binding and spectroscopic parameters for a series of mixed-ligand complexes on binding to DNA have been determined.The application of mixed-ligand complexes permits the variation in geometry, size, hydrophobicity, and hydrogen-bonding ability by systemati

Mechanistic insight into the electronic influences imposed by substituent variation in polyazine-bridged ruthenium(II)/rhodium(III) supramolecules

Unusual and unprecedented multipathway electrochemical mechanisms for a new class of supramolecular Ru/Rh bimetallic photocatalysts have been uncovered. The near isoenergetic Rh(dσ) and bridging ligand(π) molecular orbitals and a rate of halide loss that occurs on the cyclic voltammetry timescale provide a series of closely related complexes which display four different electrochemical mechanisms. A single complex displays two concurrent electrochemical pathways in marked contrast to all previously studied cis-[Rh(NN)2X2] motifs.

One- and Two-Photon Phototherapeutic Effects of RuII Polypyridine Complexes in the Hypoxic Centre of Large Multicellular Tumor Spheroids and Tumor-Bearing Mice**

During the last decades, photodynamic therapy (PDT), an approved medical technique, has received increasing attention to treat certain types of cancer. Despite recent improvements, the treatment of large tumors remains a major clinical challenge due to th

Ruthenium-artesunate complex as well as preparation method and application thereof

The invention discloses a ruthenium-artesunate complex as well as a preparation method and an application thereof, the ruthenium-artesunate complex can improve the uptake of artesunate by cells by utilizing the ruthenium complex, and after entering the cells, the ruthenium complex and artesunate synergistically play an anti-tumor role. The anti-tumor activity of the ruthenium-artesunate complex is researched. the ruthenium-artesunate complex has high antitumor activity, and compared with a traditional organic small molecule, the complex has the multi-coordination configuration, and can modify different ligands so as to achieve specific binding of the complex with a corresponding substrate.

Targeted ovarian cancer ruthenium-LHRH coupling diagnosis and treatment probe as well as preparation method and application thereof

The invention relates to a ruthenium-LHRH coupling diagnosis and treatment probe for targeting ovarian cancer as well as a preparation method and application of the ruthenium-LHRH coupling diagnosis and treatment probe. The structural formula of the ruthe

A Multi-action and Multi-target RuII–PtIV Conjugate Combining Cancer-Activated Chemotherapy and Photodynamic Therapy to Overcome Drug Resistant Cancers

PtII complexes are commonly used to treat cancer. To reduce their side effects and improve their pharmacological properties, PtIV complexes are being developed as prodrug candidates that are activated by reduction in cancer cells. Concomitantly, RuII polypyridine complexes have gained much attention as photosensitizers for use in photodynamic therapy due to their attractive characteristics. In this article, a novel PtIV–RuII conjugate, which combines cancer activated chemotherapy with PDT, is presented. Upon entering the cancer cell, the PtIV centre is reduced to PtII and the axial ligands including the RuII complex and phenylbutyrate are released. As each component has its individual targets, the conjugate exerts a multi-target and multi-action effect with (photo-)cytotoxicity values upon irradiation up to 595 nm in the low nanomolar range in various (drug resistant) 2D monolayer cancer cells and 3D multicellular tumour spheroids.